Dr. XU Ting is a recipient of the “Major National Talent Programs”. With 30 years of innovative R&D experience in the biopharmaceutical industry, he is a key driver of China’s biopharmaceutical industry transition from “me-too/follow-on” to “first‑in‑class” innovation.
Early in his career, Dr. Xu held key R&D positions at top‑tier international pharmaceutical companies including Biogen and Serono in the United States. After returning to China in 2008, he founded Suzhou Alphamab, where he developed more than 30 biosimilars. Through technology transfer and collaborations, he facilitated the successful market approval of 10 biosimilars in China, which have achieved aggregate peak sales exceeding12 billion yuan to date. In 2015, he led the spin‑out of Jiangsu Alphamab Oncology, which was successfully listed on the Main Board of the Hong Kong Stock Exchange in 2019.
Leveraging strong protein engineering and antibody discovery capabilities, Dr. Xu has led the establishment of world-class cutting‑edge proprietary technology platforms, including single-domain antibody, bispecific antibody, glycan-specific conjugation, and dual-payload conjugation, creating a modular, iterative innovation ecosystem that enables efficient, rapid output of next-generation anti-tumor drugs and continuously expands the boundaries of cancer therapy. He has developed over 10 pipeline assets with first‑in‑class (FIC) or best‑in‑class (BIC) potential. These include Envafolimab (KN035), the world’s first subcutaneous injectable PD‑L1 antibody, which was launched in 2021 and ushered in a new era of cancer immunotherapy with 30‑second subcutaneous injection; and Anbenitamab (KN026), the first HER2 bispecific antibody approved in China for second‑line and above HER2‑positive gastric cancer, which was launched in 2026. Two Phase III studies of KN026 in neoadjuvant and first‑line advanced breast cancer have demonstrated superior efficacy over the combination of trastuzumab and pertuzumab, poised to reshape the treatment landscape for HER2‑positive solid tumors. Additionally, six ADC candidates are in clinical development, among which JSKN003, a HER2 bispecific ADC, is expected to submit New Drug Application (NDA) for multiple indications in 2027.
Dr. Xu holds a B.S. in Biochemistry from Nanjing University, a Ph.D. from the Chinese Academy of Sciences, and completed postdoctoral training at Harvard University. He currently holds adjunct professorship at the Shanghai Institute of Materia Medica, the Chinese Academy of Sciences, and at Nanjing University. He has led multiple national‑level “Major New Drug Development” projects and received numerous honors such as the “Suzhou Outstanding Talent Award”. He is the inventor of over 100 patents.
Ms. LIU Yang has nearly 30 years of experience in the biotech industry, with extensive expertise in R&D of antibody drug conjugation. Prior to Alphamab Oncology, she served as Vice President of Corporate Operations at Dingfu Biotarget, a biotech company focused on Immuno-Oncology.
Ms. Liu is responsible for corporate operations, including human resources, supply chain, finance, internal control and audit, and clinical operations. In 2024, she led the reorganization, expansion, and execution-capability building of the clinical development team.
In recent years, Ms. Liu has played a core role in implementing the company's short-term goals and formulating long-term strategies. With foresight and vision, she has guided the direction of development and driven continuous organizational advancement. She has focused on building a corporate culture rooted in integrity and dedication, stimulating the team's intrinsic drive, and striving to scale new heights in the pursuit of efficient, sustainable, and high-quality development. She actively advocates for diversity and continuously enhances female leadership at all management levels, creating a platform for more outstanding women to excel.
Mr. WU Dong is a venture partner at 6 Dimensions Capital. Mr. Wu worked for Johnson & Johnson for over 10 years and served different positions including the head of Asia Pacific Innovation Center, a vice president of global engineering and emerging market research and development, the Emerging Market Innovation Centre Leader, a vice president of Research Development & Engineering, Asia Pacific and a senior director of emerging market research and development. Mr. Wu is currently the founder and an executive director of Shanghai Jiuben Technology Co., Ltd.
Mr. Wu received his bachelor’s degree in applied chemistry from Fudan University and an executive Master of Business Administration from China-Europe International Business School.
Mr. CHO Man is a senior economist. From June 2013 to June 2023, Mr. Cho served as an executive director and the president of Shanghai Pharmaceuticals Holding Co., Ltd. and held directorships in certain of its subsidiaries. From September 2020 to September 2024, he served as the chairman of Shanghai Biomedical Industrial Equity Investment Fund Partnership.
Mr. Cho previously held management positions such as chairman and general manager of Wing Fat Printing Co., Ltd., China Resources Pharmaceutical Group Limited, Sanjiu Enterprise Group, etc.
Mr. Cho obtained a bachelor’s degree in pharmacy from Sichuan University (former West China University of Medical Science) and a master’s degree in management from the School of Management of Fudan University.
Ms. WONG Yan Ki has 30 years of experience in accounting, auditing, corporate finance and capital market. Since November 2007, Ms. Wong has been an executive director of Advanced Capital Limited, where she is responsible for operation management and major decisions. Currently, she is an independent non-executive director in Betta Pharmaceuticals Co., Ltd., and two listed companies in the energy industry.
Ms. Wong previously held senior management positions including CFO and vice president of Great East Packaging Holdings Limited, Benefit Capital Limited, Shengda (Group) Holdings Ltd., etc. Ms. Wong also served as director or chairlady of the board of various public companies listed in different regions, such as Singapore, Hongkong and Nasdaq stock exchanges.
Ms. Wong obtained a bachelor of economics in international accounting from Xiamen University and an executive master degree of business administration from Cheung Kong Graduate School of Business. She has been admitted as a fellow member of several professional accounting associations in the UK, Hong Kong, Australia and other regions.
Dr. GAO Xiang is a veteran in China’s biotech industry with decades of experience bridging the realms of biotech entrepreneurship and corporate governance. He founded GemPharmatech Co., Ltd. in December 2017 and has been serving as its chairman since then. Dr. Gao has been a professor at Nanjing University since 2000, and director of the National Resource Center for Mutant Mice since 2002.
Dr. Gao previously held key research positions such as director of Model Animal Research Center and dean of the Nanjing Biomedical Research Institute of Nanjing University. Dr. Gao has led numerous national research projects and his outstanding contributions to scientific research have been recognized with prestigious awards including the National Science Fund for Distinguished Young Scholars and the Special Prize of the Ministry of Education Award for Scientific and Technological Progress.
Dr. Gao obtained a bachelor’s degree in zoology and a master’s degree in biochemistry from Nanjing University, and a Ph.D. in developmental biology and anatomy from Thomas Jefferson University. He successively conducted his postdoctoral research in Roche Institute of Molecular and The Jackson Laboratory in the United States.
